{"denoms":[{"counts":[{"groupId":"BG000","value":"438"},{"groupId":"BG001","value":"432"},{"groupId":"BG002","value":"870"}],"units":"Participants"}],"groups":[{"description":"Subjects received dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months.","id":"BG000","title":"Dabrafenib and Trametinib Combination Therapy"},{"description":"Subjects received matching placebos orally for 12 months","id":"BG001","title":"Dabrafenib and Trametinib Placebos"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"14.17","value":"50.4"},{"groupId":"BG001","spread":"13.14","value":"50.5"},{"groupId":"BG002","spread":"13.66","value":"50.4"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"195"},{"groupId":"BG001","value":"193"},{"groupId":"BG002","value":"388"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"243"},{"groupId":"BG001","value":"239"},{"groupId":"BG002","value":"482"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"432"},{"groupId":"BG001","value":"427"},{"groupId":"BG002","value":"859"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"11"}]}],"title":"Asian"}],"paramType":"NUMBER","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"}]}